Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 12/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KIF11 | P52732 | 5/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23055357 | 0.85 | MAPT (0.35) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23055509 | 0.84 | MAPT (0.34) | PIK3CDMEN1ALDH1A1MAPTALOX15 | |
| SCHEMBL23055871 | 0.84 | MAPT (0.36) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23055875 | 0.82 | MAPT (0.38) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23055447 | 0.81 | MAPT (0.37) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23055661 | 0.80 | MAPT (0.34) | PIK3CDMEN1ALDH1A1MAPTALOX15 | |
| SCHEMBL23055493 | 0.77 | MAPT (0.39) | MEN1ALDH1A1MAPTALOX15KMT2A | |
| SCHEMBL23055675 | 0.77 | KDM4E (0.35) | CREBBPALDH1A1HSD17B10BRD4 | |
| SCHEMBL23055851 | 0.77 | KIF11 (0.40) | PIK3CDALDH1A1MAPTL3MBTL1KIF11 | |
| SCHEMBL23055488 | 0.76 | KIF11 (0.38) | MEN1ALDH1A1MAPTALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-11795147-B2 | Modulators of complex I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-10-24 | — | — | US | disclosed |
| US-20210061761-A1 | MODULATORS OF COMPLEX I | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061761-A1 | MODULATORS OF COMPLEX I | NDUFAB1, NDUFV1, NDUFB7 | CREBBP 1175/4885PIK3CD 1901/4885MEN1 3979/4885 |
| US-11795147-B2 | Modulators of complex I | NDUFAB1, NDUFV1, NDUFB7 | CREBBP 1175/4885PIK3CD 1901/4885MEN1 3979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.